In terms of histone phosphorylation, the JAK2 inhibitors (ruxolitinib, fedratinib, and pacritinib) have been approved by the U.S FDA to treat MPN.726 Various clinical trials have been investigating their role in CMML, CLL, ALL, and post-MPN AML.727,728 In addition, aurora inhibitors have been developed and have shown synergism with docetaxel in apoptosis stimulation to inhibit lymphoma.729,730. This evidence concerns the gene JAK2 and myeloproliferative disorder.